Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...
BNY Mellon Small/Mid Cap Growth Fund Q3 2024 Commentary
The BNY Mellon Small/Mid Cap Growth Fund (Class A at NAV) returned 3.05% during the third quarter of 2024. Read more here.
BNY Mellon Research Growth Fund, Inc. Q3 2024 Commentary
BNY Mellon Research Growth Fund (Class A at NAV) underperformed its benchmark, the Russell 1000® Growth Index, during the ...